Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05631015
Other study ID # 2022-SDU-QILU-G008
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date January 1, 2012
Est. completion date December 31, 2023

Study information

Verified date November 2022
Source Shandong University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this study is to develop and validate a clinical decision support system based on automated algorithms. This system can use natural language processing to extract data from patients' endoscopic reports and pathological reports, identify patients' disease types and grades, and generate guidelines based follow-up or treatment recommendations


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 2000
Est. completion date December 31, 2023
Est. primary completion date October 31, 2022
Accepts healthy volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Patients aged 18 - 80 years - Patients underwent endoscopic examination Exclusion Criteria: - Patients with the contraindications to endoscopic examination - Patients with imcomplete examination information - Patients undergo endoscopy for therapy - Patients have history of upper gastrointestinal surgery - Patients with duodenal or Laryngeal neoplasms - Patients with gastrointestinal submucosal tumor

Study Design


Intervention

Other:
AI recongnize disease and generate recommendations
According the endoscopic reports and pathological reports, the decision support system recognise patients' disease types and grades, and generate guidelines based survilliance or treatment recommendations.

Locations

Country Name City State
China Qilu Hospital, Shandong University Jinan Shandong

Sponsors (1)

Lead Sponsor Collaborator
Xiuli Zuo

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The diagnostic accuracy of gastric diseases with deep learning algorithm The diagnostic accuracy of gastric diseases with deep learning algorithm 12 month
Primary The accuracy of recommentions for different disease with deep learning algorithm The accuracy of recommentions for different disease with deep learning algorithm 12 month
Secondary The diagnostic sensitivity of gastric diseases with deep learning algorithm The diagnostic sensitivity of gastric diseases with deep learning algorithm 12 month
Secondary The diagnostic specificity of gastric diseases with deep learning algorithm The diagnostic specificity of gastric diseases with deep learning algorithm 12 month
Secondary The diagnostic positive predictive value of gastric diseases with deep learning algorithm The diagnostic positive predictive valu of gastric diseases with deep learning algorithm 12 month
Secondary The diagnostic negative predictive value of gastric diseases with deep learning algorithm The diagnostic negative predictive value of gastric diseases with deep learning algorithm 12 month
Secondary The F-score of gastric diseases with deep learning algorithm The F-score of gastric diseases with deep learning algorithm 12 month
See also
  Status Clinical Trial Phase
Recruiting NCT05551416 - The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
Recruiting NCT05518929 - Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients Phase 4
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03219593 - Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT05536102 - The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy) Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Active, not recruiting NCT04082364 - Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer Phase 2/Phase 3
Withdrawn NCT03766607 - Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer Phase 2
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Completed NCT01924533 - Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. Phase 3
Terminated NCT01641939 - A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Phase 2/Phase 3
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Active, not recruiting NCT04908813 - Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer Phase 2
Active, not recruiting NCT04249739 - Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive Phase 2
Recruiting NCT05514158 - To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG) Phase 1
Recruiting NCT04931654 - A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer Phase 1/Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2